Bank of America’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49.9M | Buy |
1,333,071
+616,946
| +86% | +$22.9M | ﹤0.01% | 1702 |
|
|
2026
Q1 | $26M | Sell |
716,125
-85,189
| -11% | -$3.8M | ﹤0.01% | 2169 |
|
|
2025
Q4 | $37.3M | Buy |
801,314
+200,272
| +33% | +$8.92M | ﹤0.01% | 1765 |
|
|
2025
Q3 | $25M | Buy |
601,042
+27,760
| +5% | +$888K | ﹤0.01% | 2392 |
|
|
2025
Q2 | $16.5M | Buy |
573,282
+268,356
| +88% | +$8.29M | ﹤0.01% | 2752 |
|
|
2025
Q1 | $10.2M | Buy |
304,926
+69,645
| +30% | +$2.6M | ﹤0.01% | 3114 |
|
|
2024
Q4 | $12M | Sell |
235,281
-42,792
| -15% | -$2.39M | ﹤0.01% | 2764 |
|
|
2024
Q3 | $14.2M | Sell |
278,073
-27,096
| -9% | -$1.4M | ﹤0.01% | 2729 |
|
|
2024
Q2 | $13.7M | Sell |
305,169
-51,973
| -15% | -$2.4M | ﹤0.01% | 2625 |
|
|
2024
Q1 | $16.7M | Buy |
357,142
+12,729
| +4% | +$498K | ﹤0.01% | 2460 |
|
|
2023
Q4 | $12.3M | Buy |
344,413
+189,513
| +122% | +$5.81M | ﹤0.01% | 2655 |
|
|
2023
Q3 | $4.61M | Buy |
154,900
+34,526
| +29% | +$711K | ﹤0.01% | 3483 |
|
|
2023
Q2 | $2.17M | Sell |
120,374
-56,099
| -32% | -$1.12M | ﹤0.01% | 4159 |
|
|
2023
Q1 | $2.83M | Buy |
176,473
+52,406
| +42% | +$970K | ﹤0.01% | 4053 |
|
|
2022
Q4 | $2.27M | Buy |
124,067
+64,610
| +109% | +$1.14M | ﹤0.01% | 4136 |
|
|
2022
Q3 | $1.17M | Buy |
59,457
+5,171
| +10% | +$105K | ﹤0.01% | 4758 |
|
|
2022
Q2 | $1.01M | Sell |
54,286
-43,648
| -45% | -$871K | ﹤0.01% | 4889 |
|
|
2022
Q1 | $2.15M | Buy |
97,934
+29,837
| +44% | +$604K | ﹤0.01% | 4515 |
|
|
2021
Q4 | $1.94M | Buy |
68,097
+56,475
| +486% | +$1.39M | ﹤0.01% | 4598 |
|
|
2021
Q3 | $245K | Sell |
11,622
-1,487
| -11% | -$31.1K | ﹤0.01% | 6167 |
|
|
2021
Q2 | $247K | Buy |
13,109
+789
| +6% | +$13.9K | ﹤0.01% | 5950 |
|
|
2021
Q1 | $188K | Sell |
12,320
-7,000
| -36% | -$108K | ﹤0.01% | 6086 |
|
|
2020
Q4 | $272K | Sell |
19,320
-1,000
| -5% | -$13.9K | ﹤0.01% | 5395 |
|
|
2020
Q3 | $318K | Sell |
20,320
-514
| -2% | -$7.86K | ﹤0.01% | 5019 |
|
|
2020
Q2 | $365K | Buy |
20,834
+11,398
| +121% | +$194K | ﹤0.01% | 4848 |
|
|
2020
Q1 | $139K | Sell |
9,436
-3,562
| -27% | -$73K | ﹤0.01% | 5322 |
|
|
2019
Q4 | $326K | Buy |
12,998
+1,690
| +15% | +$32.2K | ﹤0.01% | 5316 |
|
|
2019
Q3 | $170K | Sell |
11,308
-1,305
| -10% | -$25.4K | ﹤0.01% | 5761 |
|
|
2019
Q2 | $316K | Sell |
12,613
-17,331
| -58% | -$429K | ﹤0.01% | 5374 |
|
|
2019
Q1 | $682K | Buy |
29,944
+24,012
| +405% | +$590K | ﹤0.01% | 4805 |
|
|
2018
Q4 | $179K | Buy |
5,932
+4,689
| +377% | +$132K | ﹤0.01% | 5589 |
|
|
2018
Q3 | $36K | Buy |
+1,243
| New | +$36.9K | ﹤0.01% | 6334 |
|
Other funds holding CRNX
FCM
DCM
JT
Bank of America's CRNX Position: Q2 2026 in Review
Bank of America increased its Crinetics Pharmaceuticals (CRNX) stake by 86% in Q2 2026, buying an estimated $22.9M and bringing the position to 1,333,071 shares worth $49.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1702.
Bank of America first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Bank of America held 1,333,071 shares of Crinetics Pharmaceuticals worth $49.9M as of Q2 2026.
- Bank of America bought 616,946 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $22.9M.
- Crinetics Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1702 holding.
- Bank of America first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.